JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.47 8.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.25

Max

2.61

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+404.39% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	69M 616M
Eelmine avamishind	-5.86
Eelmine sulgemishind	2.47

Uudiste sentiment

By Acuity

65%

35%

322 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. veebr 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. veebr 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. veebr 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. veebr 2026, 23:23 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. veebr 2026, 22:57 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. veebr 2026, 21:51 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. veebr 2026, 21:49 UTC

Tulu

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. veebr 2026, 21:39 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:36 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. veebr 2026, 21:34 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 21:23 UTC

Tulu

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. veebr 2026, 21:19 UTC

Tulu

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. veebr 2026, 21:17 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. veebr 2026, 21:17 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:10 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:08 UTC

Tulu

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. veebr 2026, 21:07 UTC

Tulu

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Net $608.7M >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Rev $1.41B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q EPS 24c >PLTR

2. veebr 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

404.39% tõus

12 kuu keskmine prognoos

Keskmine 11.5 USD 404.39%

Kõrge 15 USD

Madal 9 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

322 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.